Further studies are needed to assess the potential cardiovascular and renal benefits of combination therapy and to determine suitable patient population for the therapy
The biggest challenge with silymarin is its low bioavailability
DOI: Published online: December 26, 2022 1 Laboratory of Endocrinology and Immune System, Chungnam National University College of Medicine, Daejeon, Korea 2 Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea 3 Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea 4 Department of Biochemistry, Chungnam National University College of Natural Sciences, Daejeon, Korea 5 Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka, Japan Corresponding authors: Hyon-Seung Yi
Citations [1] Kwon DR, Park GY